Biocept

Biocept

Biocept

Biocept improves cancer outcomes with its industry-leading liquid biopsy tests.
Type
B2c
Founded
1993
Raised
$9.3M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$9,300,000
Post-IPO equity - 2017
ROTH Capital Partners Chardan Capital
Team Size
50+
Employees
$9,300,000 Post-IPO equity
biospace

SoCals Biocept Rakes in 9 3 Million Financing

Stock markets Legal Health